Literature DB >> 9499099

Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity.

H Gahéry-Ségard1, F Farace, D Godfrin, J Gaston, R Lengagne, T Tursz, P Boulanger, J G Guillet.   

Abstract

Replication-deficient adenovirus used in humans for gene therapy induces a strong immune response to the vector, resulting in transient recombinant protein expression and the blocking of gene transfer upon a second administration. Therefore, in this study we examined in detail the capsid-specific humoral immune response in sera of patients with lung cancer who had been given one dose of a replication-defective adenovirus. We analyzed the immune response to the three major components of the viral capsid, hexon (Hx), penton base (Pb), and fiber (Fi). A longitudinal study of the humoral response assayed on adenovirus particle-coated enzyme-linked immunosorbent assay plates showed that patients had preexisting immunity to adenovirus prior to the administration of adenovirus-beta-gal. The level of the response increased in three patients after adenovirus administration and remained at a maximum after three months. One patient had a strong immune response to adenovirus prior to treatment, and this response was unaffected by adenovirus administration. Sera collected from the patients were assayed for recognition of each individual viral capsid protein to determine more precisely the molecular basis of the humoral immune response. Clear differences existed in the humoral response to the three major components of the viral capsid in serum from humans. Sequential appearance of these antibodies was observed: anti-Fi antibodies appeared first, followed by anti-Pb antibodies and then by anti-Hx antibodies. Moreover, anti-Fi antibodies preferentially recognized the native trimeric form of Fi protein, suggesting that they recognized conformational epitopes. Our results showed that sera with no neutralizing activity contained only anti-Fi antibodies. In contrast, neutralizing activity was only obtained with sera containing anti-Fi and anti-Pb antibodies. More importantly, we showed that anti-native Fi and anti-Pb antibodies had a synergistic effect on neutralization. The application of these conclusions to human gene therapy with recombinant adenovirus should lead to the development of strategies to overcome the formation of such neutralization antibodies, which have been shown to limit the efficacy of gene transfer in humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9499099      PMCID: PMC109538          DOI: 10.1128/JVI.72.3.2388-2397.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery.

Authors:  S Huang; R I Endo; G R Nemerow
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

2.  Cystic fibrosis. Vehicles for gene therapy.

Authors:  J M Wilson
Journal:  Nature       Date:  1993-10-21       Impact factor: 49.962

3.  Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: role of the immune response.

Authors:  H Gilgenkrantz; D Duboc; V Juillard; D Couton; A Pavirani; J G Guillet; P Briand; A Kahn
Journal:  Hum Gene Ther       Date:  1995-10       Impact factor: 5.695

4.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses.

Authors:  Y Yang; Q Li; H C Ertl; J M Wilson
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

5.  Multiple adenovirus serotypes use alpha v integrins for infection.

Authors:  P Mathias; T Wickham; M Moore; G Nemerow
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

6.  Oligomerization of recombinant penton base of adenovirus type 2 and its assembly with fiber in baculovirus-infected cells.

Authors:  L Karayan; B Gay; J Gerfaux; P A Boulanger
Journal:  Virology       Date:  1994-08-01       Impact factor: 3.616

7.  Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B.

Authors:  W S Gallichan; D C Johnson; F L Graham; K L Rosenthal
Journal:  J Infect Dis       Date:  1993-09       Impact factor: 5.226

8.  Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase.

Authors:  F W Van Ginkel; C Liu; J W Simecka; J Y Dong; T Greenway; R A Frizzell; H Kiyono; J R McGhee; D W Pascual
Journal:  Hum Gene Ther       Date:  1995-07       Impact factor: 5.695

9.  Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung.

Authors:  Y Yang; G Trinchieri; J M Wilson
Journal:  Nat Med       Date:  1995-09       Impact factor: 53.440

10.  MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.

Authors:  Y Yang; H C Ertl; J M Wilson
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

View more
  67 in total

1.  Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies.

Authors:  C Goldmann; H Petry; S Frye; O Ast; S Ebitsch; K D Jentsch; F J Kaup; F Weber; C Trebst; T Nisslein; G Hunsmann; T Weber; W Lüke
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Episomal segregation of the adenovirus enhancer sequence by conditional genome rearrangement abrogates late viral gene expression.

Authors:  X Wang; W Zeng; M Murakawa; M W Freeman; B Seed
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product.

Authors:  Stéphanie Mercier; Hanne Gahéry-Segard; Martine Monteil; Renée Lengagne; Jean-Gérard Guillet; Marc Eloit; Caroline Denesvre
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

4.  Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.

Authors:  Hongju Wu; Igor Dmitriev; Elena Kashentseva; Toshiro Seki; Minghui Wang; David T Curiel
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.

Authors:  Ritu R Bradley; Lori F Maxfield; Diana M Lynch; Mark J Iampietro; Erica N Borducchi; Dan H Barouch
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

6.  Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.

Authors:  Shawn M Sumida; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Wouter Koudstaal; Maria G Pau; Stefan Kostense; Menzo J E Havenga; Jaap Goudsmit; Norman L Letvin; Dan H Barouch
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

7.  Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.

Authors:  Ritu R Bradley; Diana M Lynch; Mark J Iampietro; Erica N Borducchi; Dan H Barouch
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 8.  Genomic foundations of evolution and ocular pathogenesis in human adenovirus species D.

Authors:  Ashrafali Mohamed Ismail; Xiaohong Zhou; David W Dyer; Donald Seto; Jaya Rajaiya; James Chodosh
Journal:  FEBS Lett       Date:  2019-12-11       Impact factor: 4.124

Review 9.  Applying horizontal gene transfer phenomena to enhance non-viral gene therapy.

Authors:  Jacob J Elmer; Matthew D Christensen; Kaushal Rege
Journal:  J Control Release       Date:  2013-08-30       Impact factor: 9.776

10.  Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors.

Authors:  Saw See Hong; Nagy A Habib; Laure Franqueville; Steen Jensen; Pierre A Boulanger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.